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Iron deﬁciency (ID) is relatively common among the elderly population, contributing
substantially to the high prevalence of anemia observed in the last decades of life, which
in turn has important implications both on quality of life and on survival. In elderly subjects,
ID is often multifactorial, i.e., due to multiple concurring causes, including inadequate
dietary intake or absorption, occult bleeding, medications. Moreover, because of the typical
multimorbidity of aged people, other conditions leading to anemia frequently coexist and
make diagnosis of ID particularly challenging.Treatment of ID is also problematic in elderly,
since response to oral iron is often slow, with a substantial fraction of patients showing
refractoriness and requiring cumbersome intravenous administration. In the last decade,
the discovery of the iron regulatory hormone hepcidin has revolutionized our understanding
of iron pathophysiology. In this review, we revisit ID among elderly people in the light of the
impressive recent advances on knowledge of iron regulation, and discuss how hepcidin
may help in diagnosis and treatment of this common clinical condition.
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ANEMIA IN ELDERLY, PREVALENCE, AND DEFINITION
Anemia is a common, multi-factorial condition in elderly. Indeed,
the prevalence of anemia increases with age, representing an
important health problem among older individuals. Large studies
on community-dwelling older adults from the United States and
Europe have reported prevalence rates for anemia ranging from
8 to 25% (Patel, 2008). One of the largest population survey, i.e.,
the third US National Health and Nutrition Examination Survey
(NHANES III), indicated that 10.2% of women and 11% of men
>65 years of age were anemic (Guralnik et al., 2004). These frac-
tions rose to 26.1 and to 20.1% in subjects older than 85 years old,
in males and females, respectively (Guralnik et al., 2004).
There is some debate on which hemoglobin (Hb) threshold
should be used to deﬁne anemia in the general population and
particularly in elderly individuals (Beutler and Waalen, 2006). In
many studies, anemia has been deﬁned according to the World
Health Organization (WHO) criteria (Blanc et al., 1968) as a Hb
level<13 g/dL inmen and<12 g/dL inwomen, respectively. How-
ever, these criteria have been criticized since they were based on
statistical distributions (i.e., equivalent to two standard deviations
below the mean) in reference samples that did not include indi-
viduals >65 years of age, making unfeasible their application to
older individuals (Mindell et al., 2013). Since Hb values in appar-
ently healthy elderly individuals are generally lower than those in
younger adults and the differences betweenmales and females tend
to disappear with aging (Patel, 2008), a Hb value< 12 g/dL is now
commonly considered indicative of anemia in elderly of both sexes
(Izaks et al., 1999; Andrès et al., 2013).
Anemia in elderly is typically hyporegenerative and relatively
mild, with Hb levels near 10–11 g/dL in most subjects (Gural-
nik et al., 2004). Nevertheless, it is associated with a variety of
adverse outcomes, including longer hospitalization, disability, and
increased mortality risk (Chaves et al., 2004; Zakai et al., 2005;
Culleton et al., 2006; Denny et al., 2006; Penninx et al., 2006; den
Elzen et al., 2009; Price et al., 2011). Moreover, it also signiﬁcantly
impacts on the quality of life, being associated with fatigue, cogni-
tive dysfunction, depression, decreased muscle strength, falls, and
“frailty,” even when Hb levels are merely low-normal (Woodman
et al., 2005; Eisenstaedt et al., 2006).
Approximately, one-third of the cases of anemia in elderly can
be ascribed to a chronic disease (inﬂammation and chronic kid-
ney diseases), and one-third is due to nutrient deﬁciencies (folate,
B12, and iron). Iron deﬁciency (ID), alone or in combination
with deﬁciency of other nutrients, accounts for more than one-
half of this group. The last third remains “unexplained” (Guralnik
et al., 2004). Noteworthy, a signiﬁcant proportion of elderly ane-
mic patients (30–50%) is presumed to have multiple causes of
anemia (Petrosyan et al., 2012). Since elderly patients are typically
affected by several different pathologic conditions (multimorbid-
ity), and are commonly taking a long list of medications, the
precise etiology of anemia is often difﬁcult to determine in a given
individual (Andrès et al., 2013), and sometimes remains “unex-
plained” despite extensive investigation (Guralnik et al., 2004).
Thinking in terms of multimorbidity is a key to understanding,
diagnosis, and treatment of anemia in the elderly.
IRON DEFICIENCY IN ELDERLY
According to the WHO, ID is by far the most common and
widespread nutritional disorder worldwide (http://www.who.int/
nutrition/topics/ida/en/), with estimated one billion people
affected, thus constituting a public health condition of epidemic
proportions. Besides the large number of children and young
women affected in developing countries, ID is the only nutri-
ent deﬁciency that is also signiﬁcantly prevalent in industrialized
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countries [World Health Organization (WHO), 2001; Hershko
and Camaschella, 2013], where an additional category at risk is
represented by elderly people (Guyatt et al., 1990).
Iron deﬁciency syndromes include a range of different condi-
tions (Goodnough, 2012). “Absolute” ID is deﬁned by the lack of
storage iron (Cook, 2005; Fairweather-Tait et al., 2013). In phys-
iological conditions, the total body iron amount (near 3–4 g) is
maintained by a ﬁne balance between three distinct factors: body
requirements, iron supply (depending on dietary iron intake and
duodenal absorption), and blood losses. While an increased iron
demand is the main cause of ID in children and fertile females,
insufﬁcient dietary iron intake, gastrointestinal (GI) malabsorp-
tion and/or increased blood losses are the most common causes
of ID in older individuals (see below).
At variance with “absolute” ID, many disorders are character-
ized by the so-called “functional” or “relative” ID, deﬁned as the
occurrence of iron-restricted erythropoiesis in presence of normal
or even increased amounts of body iron stores. This phenomenon
is often related to an impaired iron trafﬁcking (i.e., block of
iron release from macrophages and hepatocytes, typically dur-
ing inﬂammatory diseases) or to increased/ineffective/stimulated
erythropoiesis, with iron demand exceeding the supply (i.e., dur-
ing hemoglobinopathies, chronic hemolytic anemias or treatment
with erythropoiesis stimulating agents). Since the focus of this
article is on etiology, diagnosis, and management of the absolute
ID in elderly, the readers are referred to others excellent reviews for
details on the functional ID syndromes (Goodnough et al., 2010,
Goodnough, 2012; Auerbach et al., 2013a).
Whatever the mechanism, both absolute and functional ID
reduce iron availability to erythroid precursors, with the develop-
ment of an iron-restricted erythropoiesis, and ﬁnally of anemia.
In particular, two ID stages can be distinguished: (a) initial, char-
acterized by reduced transferrin saturation but without anemia;
and (b) advanced, when microcytic, hypochromic iron-deﬁciency
anemia (IDA) becomes evident.
In elderly, ID and IDA are nearly always due to chronic GI
diseases, which in turn lead to iron loss and malabsorption
not infrequently occurring in combination at individual level
(Figure 1). Indeed, the most frequent cause is represented by
chronic upper and lower GI blood losses, because of esophagi-
tis, gastritis, peptic ulcer, colon cancer or pre-malignant polyps,
inﬂammatory bowel disease, or angiodysplasia (Eisenstaedt et al.,
2006). The prevalence of most of these conditions increases with
age, which is particularly true for neoplastic lesions (Eddy, 1990)
and angiodysplasia (Sami et al., 2014). Remarkably, GI bleeding
is typically increased by concomitant assumption of medica-
tions for conditions highly prevalent in elderly individuals, such
as non-steroidal anti-inﬂammatory drugs for osteoarthritis, and
antithrombotic therapies for cardiovascular disease, especially for
atrial ﬁbrillation.
FIGURE 1 | Gastrointestinal diseases representing the most frequent
causes of ID and IDA in elderly patients. Of note, more than one of these
conditions not infrequently coexist in a given individual. Bleeding is often
favored by antithrombotic drugs for treatment of cardiovascular diseases that
are highly prevalent in this age group. Suggested diagnostic tools are
reported on the right side. AAG, autoimmune atrophic gastritis; CD, celiac
disease; GI, gastrointestinal; HP, Helicobacter pylori ; IBD, inﬂammatory bowel
disease; PPI, proton pump inhibitors; VCE, video capsule endoscopy.
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Iron malabsorption is also relatively frequent in the elderly.
Indeed, further conditions whose prevalence typically increases
with age are represented by Helicobacter pylori (HP) infection
(Pounder and Ng, 1995) and atrophic gastritis. Of note, although,
for a long time, celiac disease (CD) has been primarily consid-
ered an enteropathy of childhood and young adults, a number of
epidemiological studies have reported an increased detection rate
in older subjects, with up to one third of newly diagnosed patients
being older than 65 years (Patel et al., 2005; Rashtak and Murray,
2009; Vilppula et al., 2009). In this age group, multifactorial ane-
mia is the most frequent clinical presentation (Harper et al., 2007),
with micronutrients deﬁciency (particularly ID) being the leading
cause. For poorly understood reasons, the classical triad of malab-
sorptive symptoms including diarrhea, weight loss and abdominal
pain is less common in elderly (Freeman, 2008), making the diag-
nosis frequently overlooked in this age category. Another factor
that could theoretically contribute to ironmalabsorption in elderly
patients is represented by the frequent long-term use of proton
pump inhibitors (PPI), being gastric acid essential for optimal
intestinal absorption of the element (Ganz, 2013). However, only
few reports have speciﬁcally addressed this issue, which remains
controversial (Reimer, 2013).
Typically, all the above-mentioned conditions impairing iron
absorption share a clinical phenotype of refractoriness to oral iron
therapy, recently named“acquired IRIDA”(iron refractory ID ane-
mia; for a review see Hershko and Camaschella, 2013). These
conditions should be always considered in elderly subjects with
IDA and no evidence of GI blood loss.
Finally, malnutrition is an obvious contributing factor to ID in
elderly. However, since iron requirement (1–2 mg/day) only corre-
sponds to near 10% of the average daily iron intake, malnutrition
is rarely sufﬁcient per se to cause IDA, at least in industrialized
countries. Nevertheless, evaluation of the patient’s nutritional sta-
tus plays an important role in the diagnostic approach to anemia
in the older adult.
HEPCIDIN, THE KEY REGULATOR OF IRON HOMEOSTASIS
Hepcidin, a defensin-like hormone synthesizedmainly by the liver,
has been discovered in 2001 and recognized as the master regu-
lator of iron metabolism (Ganz and Nemeth, 2011). The active
form of hepcidin is a 25-amino acid peptide derived from an
84 amino acid precursor, but at least two others isoforms trun-
cated at the N-terminus, i.e., hepcidin-20 and hepcidin-22, have
been also identiﬁed in biological ﬂuids (Castagna et al., 2010).
The biological meaning of these isoforms is still unclear (Cam-
postrini et al., 2012). Hepcidin acts by binding to its receptor, the
transmembrane protein ferroportin, which currently represents
the only known cellular iron exporter in mammals (De Domenico
et al., 2011). In humans, ferroportin is mainly expressed in cells
playing a key role in iron homeostasis, like duodenal enterocytes
(absorption of dietary iron), in splenic and hepatic macrophages
(recycling iron from erythrophagocytosis), and in hepatocytes
(iron stores). The hepcidin-ferroportin binding induces the endo-
cytosis and the lysosomal degradation of both molecules, resulting
in decreased intestinal absorption and release of iron from recy-
cling macrophages, both ultimately leading to reduction of plasma
iron concentration (Ganz and Nemeth, 2011). Regulation of
hepcidin synthesis is quite complex and includes a number of dif-
ferent pathways [for recent detailed reviews see Ganz (2013) and
Meynard et al. (2014)]. ID and increased erythropoietic activity
down-regulate hepcidin production, and suppressed or very low
hormone concentrations are observed in IDAor anemiaswith high
erythropoietic activity (Ganz et al., 2008). Although the nature of
the suppressive signal is still unknown, there is some evidence
that, at least in conditions of stimulated erythropoiesis, it could be
represented by a circulating factor produced by the erythroid pro-
genitors in the bone marrow (Kautz et al., 2013). On the other
hand, hepcidin is strongly induced by inﬂammation (Nemeth
et al., 2003, 2004), in particular by the pro-inﬂammatory cytokine
interleukin-6 (IL-6), and it is responsible for iron-limited erythro-
poiesis in patients with acute and chronic inﬂammatory states
(Ganz, 2003; McCranor et al., 2013). Nevertheless, recent studies
in mouse models (Gardenghi et al., 2014; Kim et al., 2014) have
suggested that the iron-restricted anemia induced by inﬂamma-
tion likely recognizes a more complex pathogenesis, only partially
dependent on hepcidin.
Currently, two main methods are available for measuring hep-
cidin in blood and urine, immunoassays based on anti-hepcidin
antibodies, and mass spectrometry (MS)-based assays (Castagna
et al., 2010; Kroot et al., 2011). The latters are generally prefer-
able, being able to distinguish the iron bioactive 25-mer isoform
from other isoforms of uncertain signiﬁcance, at variance with
the incomplete speciﬁcity of available antibodies (Castagna et al.,
2010; Kroot et al., 2011). Serum hepcidin shows well-deﬁned
age- and sex-speciﬁc variations at population level as illustrated
below (Galesloot et al., 2011; Traglia et al., 2011). The measure-
ment of hepcidin in biological ﬂuids represents a promising tool
in the diagnosis and management of conditions characterized by
an altered iron homeostasis, including ID/IDA. However, a “gold
standard”method available for daily clinical practice at reasonable
costs is stills lacking.
HEPCIDIN LEVELS IN ELDERLY
The “unexplained” anemia of elderly has been linked to two puta-
tive mechanisms, namely a progressive resistance of bone marrow
erythroid progenitors to erythropoietin (EPO), and a chronic sub-
clinical pro-inﬂammatory state (Vanasse and Berliner, 2010). In
this context, hepcidin could theoretically play a substantial role,
considering its involvement both in inﬂammation and in the reg-
ulation of iron availability for erythropoiesis. Indeed, previous
studies have showed a mild increase of inﬂammatory markers
like tumor necrosis factor alpha (TNF-α) and IL-6, a major hep-
cidin inducer, in elderly subjects (Andrews, 2004; Ferrucci et al.,
2005; Maggio et al., 2006). To date, only two studies, the Nijmegen
biomedical studies (NBS; Galesloot et al., 2011), and the Val Bor-
bera studies (VBS; Traglia et al., 2011), have investigated serum
hepcidin levels at population level in apparently healthy subjects,
including elderly groups. Both studies showed that before the
menopause hepcidin levels in women are nearly 50% lower than
in males of corresponding ages. After the menopause, hepcidin
levels tend to be similar in both sexes, with a slight decrease in the
eldest groups. This was evident in both sexes in theVBS (Figure 2),
but only in males in the NBS. Although not speciﬁcally designed
to study the anemia of elderly, these studies tended to exclude a
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FIGURE 2 | Serum hepcidin (A) and ferritin (B) levels stratified by
decades in healthy subjects older than 50 years. Subjects were from the
Val Borbera study, a large population survey including 1657 subjects.
Adapted fromTraglia et al. (2011).
sustained increase of hepcidin in elderly. Accordingly, two studies
in elderly anemic patients have failed to detect increased hepcidin
levels in urine (Ferrucci et al., 2010) and in serum (Waalen et al.,
2011), and even a correlation between hepcidin and IL-6 or TNF-α
(Ferrucci et al., 2005).
On the contrary, the Leiden 85-plus Study, a population-based
prospective study in 85-year old subjects from Leiden (the Nether-
lands), showed that in this age group C-Reactive Protein (a proxy
for IL-6) was a signiﬁcant predictor of circulating hepcidin levels,
which in turn were relatively higher in a small subgroup (n = 29)
with unexplained anemia (den Elzen et al., 2013). Several reasons
may account for these discrepancies on hepcidin levels in elderly
anemic subjects, including the different laboratory methods and
clinical settings (Goodnough and Schrier, 2014). Most of the data
are retrospective, and properly designed, large-scale, studies are
required before drawing deﬁnite conclusions. For the moment,
the available evidence has generally downsized the initial hypoth-
esis on hepcidin as amajor determinant of the unexplained anemia
of the elderly. This remains likely a complex condition due to the
combinationof several age-related changes, such as stemcell aging,
low-grade chronic inﬂammation, subclinical impairment of kid-
ney function, androgen insufﬁciency, and others still unknown
(Guralnik et al., 2004; Makipour et al., 2008).
DIAGNOSIS OF IDA IN ELDERLY
Several guidelines and recommendations have been proposed for
the diagnosis of IDA in the general population (Cook, 2005;
Goddard et al., 2011), but there is no consensus regarding the opti-
mal approach for the diagnosis and management of IDA in elderly.
Nevertheless, it is clear that, besides iron supplementation, the
general principle of searching, and if possible treating, the under-
lying cause(s) should be pursued also in elderly patients (Andrès
et al., 2013). Being GI diseases the most common causes of IDA
in elderly (Figure 1), the diagnostic work-up should often, at least
theoretically, include relatively invasive investigations, like endo-
scopic procedures. This is particularly true since, for example, IDA
in elderly often herald the presence of an occult GI malignancy. Of
course, old age per se is not a contraindication to such procedures,
but a particular clinical skill is required in each individual and frail
elderly patient to thoroughly evaluate the risk-beneﬁt ratio as well
as the prognostic implications.
Anyway, while the diagnostic work-up should be, when-
ever possible, comprehensive, some conditions deserve peculiar
attention in the elderly patient presenting with IDA.
In our experience, a condition particularly challenging is repre-
sented byGI angiodysplasia, which in turn is a potentially treatable
disease (Richter et al., 1984). Remarkably, bleeding inGI angiodys-
plasia is often discontinuous, with possible false negativity of
occult fecal blood test. Moreover, although most of GI angiodys-
plasia lesions are localized in the colon (54–82% are in the cecum
and in ascending colon), they can escape to a single endoscopy,
or be localized in the small bowel, which is not routinely investi-
gated. In this case, additional testing by video capsule endoscopy
(VCE) is needed (Sami et al., 2014). Finally, a distinct feature of
GI angiodysplasia is its frequent association with another rela-
tively common condition in elderly, i.e., aortic stenosis, which
occurs in near one third of patients (Batur et al., 2003). This
association, known as Heyde’s syndrome, is notably characterized
by a coagulopathy, i.e., acquired von Willebrand disease (Vin-
centelli et al., 2003), due to shear-stress mediated consumption
of high molecular weight multimers of the von Willebrand fac-
tor (Loscalzo, 2012). Being the latters the most hemostatically
competent form of von Willebrand factor, this favors a vicious
circle that aggravates the bleeding from GI angiodysplasia and the
consequent IDA.
From a laboratory point of view, an accurate diagnosis of IDA
in elderly is also challenging because of the high prevalence of
concomitant chronic diseases that complicate the interpretation
of traditional biomarkers. The red blood cells mean corpuscu-
lar volume (MCV) is often a starting index in the evaluation of
a patient with anemia, being typically reduced in IDA. However,
MCV reduction in elderly is often lacking in early stages and/or
blunted by other concomitant nutritional deﬁciencies, such as
those of folic acid or vitamin B12. Similarly, the other common
laboratory markers of “absolute” ID, i.e., low serum ferritin and
transferrin saturation, and raised transferrin, have a low sensi-
tivity in elderly (Fairweather-Tait et al., 2013). For example, the
classical cut-off value of serum ferritin ≤12–15 μg/L, which com-
monly deﬁnes ID in younger adults (Lipschitz et al., 1974; Ali et al.,
1978; Carmel, 2008), has been claimed as too stringent in elderly
patients. Indeed, in these subjects true ID often occurs at higher
ferritin values, since ferritin per se raises with aging (Casale et al.,
1981), and is an acute-phase reactant that increase during inﬂam-
mation, infection, malignancy, and other illnesses common in
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older people. In a study carried out in hospitalized older patients,
a serum ferritin level <50 μg/L resulted more reliable in predict-
ing ID than other traditional cut-off values (Joosten et al., 1991).
The low sensitivity of traditional iron biomarkers is demonstrated
also by the fact that elderly anemic patients sometimes respond to
iron supplementation even if their iron indices at baseline are not
abnormal (Price et al., 2011).
Soluble transferrin receptor (sTfR), derived from proteolysis of
the membrane transferrin receptor (TR), reﬂects erythropoietic
activity and inversely correlates with the amount of iron avail-
able for erythropoiesis. In the past, some evidence supported
sTfR measurement as a novel marker of ID in older people,
considering that its levels do not increase with age and are not
affected by the presence of inﬂammation (Mast et al., 1998). In
particular, the serum sTfR divided by the log of the ferritin
(sTfR-ferritin index) was found useful in classifying patients with
ACD and concomitant IDA (Punnonen et al., 1997; Rimon et al.,
2002). However, currently the lack of standardized reagents for
the sTfR assay complicates interpretation of the sTfR-ferritin
index in different studies, and limits its use in clinical practice
(Pfeiffer et al., 2007).
In the last decade, hepcidin has been suggested as a promising
diagnostic marker for iron-related disorders (Goodnough et al.,
2010; Kroot et al., 2011). In IDA serum and urinary hepcidin lev-
els are typically reduced and frequently undetectable by currently
available assays (Bozzini et al., 2008; Ganz et al., 2008; Castagna
et al., 2010). Hepcidin suppression appears also a sensitive indi-
cator of ID without anemia, since decreased levels have been
observed prior to a detectable decrease in Hb or hematocrit (Ganz
et al., 2008; Pasricha et al., 2011). As mentioned above, hepcidin
is induced by inﬂammatory cytokines and contributes to the
pathogenesis of the so-called anemia of chronic disease (ACD),
which is characterized by impaired iron utilization, along with
inadequate EPO production, and cytokine-induced inhibition of
erythroid precursors (Weiss and Goodnough, 2005). The opposite
trendof hepcidin in IDAversusACDhas theoretically the potential
to differentiate these conditions, both highly prevalent in elderly,
and not infrequently coexisting. Of note, preclinical studies have
shown that concomitant ID tends to blunt the hepcidin response
to pro-inﬂammatory cytokines (Theurl et al., 2009; Darshan et al.,
2010), suggesting the possibility to distinguish in the individual
anemic patient the presence of IDA or mixed IDA/ACD (both with
low to undetectable hepcidin levels) from ACD alone (with high
hepcidin levels). Preliminary data in patients with rheumatoid
arthritis (van Santen et al., 2011) or inﬂammatory bowel disease
(Bergamaschi et al., 2013) are consistent with this possibility, but
larger data are required for conﬁrmation, particularly in elderly
subjects where the distinction between IDA and ACD is expected
to be particularly challenging.
TREATMENT OF IDA IN ELDERLY
Currently, no speciﬁc guidelines exist for the management of ane-
mia in the elderly. A recent review recommends that iron status
should be checked at ﬁrst in every elderly patient (Goodnough
and Schrier, 2014). Once IDA is clearly ascertained or deemed
likely (because of ambiguous results of iron markers as discussed
above) a therapeutic trial with oral iron should be prescribed,
with the aim of correcting both anemia and iron stores. This
ﬁrst-line approach, preferably using divalent compounds like fer-
rous sulfate or gluconate because of their superior bioavailability
(Clark, 2009), is usually considered to be safer for the patient and
with a better cost-effective ratio as compared to parenteral iron
administration.
In general, Hb levels are expected to rise by approximately
1–2 g/dL every couple of weeks after starting oral iron therapy
(Clark, 2008), which should be continued for 3 months after
correction of anemia to replenish iron stores. The time needed
may be even longer in elderly patients, because of slower bone
marrow response. This translates in poor adherence, particu-
larly when concomitant multimorbidity requires the assumption
of a huge number of pills per day. Moreover, oral iron supple-
mentation is often poorly tolerated in elderly patients, particu-
larly because abdominal discomfort, as well as poorly absorbed
because of the relative highprevalence of malabsorptive conditions
(see above).
Thus, intravenous (IV) iron replacement is often required in
elderly patients with IDA (Silverstein and Rodgers, 2004; Clark,
2009; Pasricha et al., 2010). Most IV iron formulations are gener-
ally effective, well tolerated, and with a lower incidence of serious
adverse reaction (e.g., anaphylaxis) than commonly thought by
many clinicians (Fishbane, 2003; Auerbach and Ballard, 2010;
Auerbach et al., 2013a). Until a few years ago, the most widely
used formulations in Europe were iron gluconate or iron sucrose,
which are relatively unstable compounds with limited maximal
doses per single infusion, i.e., 125 and 200 mg, respectively.
Since the mean total iron dose generally required to correct ane-
mia and restore iron is 1000–1500 mg, multiple hospital accesses
for repeated infusions are needed. In elderly patients with lim-
ited autonomy, this not only increases direct and indirect social
costs, but also can substantially hamper the feasibility of the
treatment.
Recently, the pharmaceutical industry hasmade signiﬁcant pro-
gresses through the production of more stable iron compounds
that can be safely administered at high doses per single infusion,
i.e., 1000–1500 mg, thus allowing a single treatment episode (for
a review see Auerbach et al., 2013a). These includes low molecular
weight iron dextran (Auerbach et al., 2011), ferumoxytol (Auer-
bach et al., 2013b), iron isomaltoside (Wikstrom et al., 2011), and
ferric carboxymaltose (Evstatiev et al., 2011; Onken et al., 2014).
These preparations signiﬁcantly simplify the IV iron therapy, an
effect that is expected to be particularly useful in elderly patients
with IDA. However, speciﬁc trials in this setting are needed to
conﬁrm these exciting promises. Moreover, IV iron has theoreti-
cally the potential to generate oxidative stress and inﬂammatory
cytokine production, and to increase susceptibility to certain infec-
tions, so that its long-term effects also need further future studies
(Auerbach and Ballard, 2010; Goodnough et al., 2010).
Since hepcidin inhibits duodenal iron absorption, it has been
suggested that measuring hormone levels may help to determine
a priori the best way of iron administration, oral, or IV, in a
given individual. Indeed, in a recent retrospective study, hep-
cidin levels were proven useful in identifying IDA patients who did
not respond to oral iron supplementation (Bregman et al., 2013).
Of note, the cut-off value of serum hepcidin that discriminated
www.frontiersin.org April 2014 | Volume 5 | Article 83 | 5
Busti et al. Iron deﬁciency in the elderly
between responders (R) and not responders (NR) to oral iron was
not particularly high (20 ng/ml), and within the “normal” range
for the method employed (Bregman et al., 2013). The positive
predictive value of NR for hepcidin levels >20 ng/ml was 81.4%.
On the contrary, the majority of R patients had very low to com-
pletely suppressed (undetectable) hepcidin levels, as is the general
rule for IDA patients (see above). If these data will be conﬁrmed by
further studies, hepcidin assay could actually help to individualize
iron therapy, by avoiding waste of time with a poorly tolerated
oral therapy when hormone levels are high or “pseudonormal,”
particularly in elderly patients. In a near future scenario, a possible
algorithm for the diagnosis and treatment of IDA in elderly, based
on most recent pathophysiological and therapeutic advances in
the ﬁeld, is depicted in Figure 3.
CONCLUSION
Iron deﬁciency is a major cause of anemia in elderly patients,
and should be always searched as ﬁrst diagnostic step. IDA in
FIGURE 3 | Possible algorithm for the diagnosis and treatment of
IDA in elderly in a near future scenario. The proposed algorithm is
based on most recent pathophysiological and therapeutic advances in
the ﬁeld. Dotted lines for evaluation of hepcidin levels indicate that the
available data suggesting this approach (Bregman et al., 2013) need
conﬁrmation by future studies. Similarly, before this approach enters the
clinical practice, a better standardization of hepcidin assays is
needed. AAG, autoimmune atrophic gastritis; AI, anemia of
inﬂammation; CD, celiac disease; CKD, chronic kidney disease; GI,
gastrointestinal; Hb, hemoglobin; HM, hematologic malignancies; HP,
Helicobacter pylori; IDA, iron deﬁciency anemia; MDS, myelodysplastic
syndrome; TS, transferrin saturation.
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elderly is not infrequently multifactorial and difﬁcult to diagnose
since traditional biochemical markers of iron status are relatively
ambiguous in this age group. Reasoning in terms of multimorbid-
ity is central for a correct approach to IDA in elderly. Being GI
blood loss the major cause of IDA in elderly, a correct identiﬁ-
cation of the bleeding source can be lifesaving, particularly when
an occult malignancy is underlying. The discovery of hepcidin
has revolutionized our understanding of iron metabolism, and
measuring hormone levels may help both in diagnosis and in
selecting the best treatment option, particularly as the IV ther-
apy is becoming simpler than ever with the availability of new iron
compounds.
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